MedTrace Logo

Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532

NCT01388829 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-08-10

No results posted yet for this study

Summary

This study is designed to compare the pharmacokinetics of two different lots of tablets.

Conditions

  • Healthy

Interventions

DRUG

Treatment A

150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot

DRUG

Treatment B

150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01388829 on ClinicalTrials.gov